Rheumatoid Arthritis
Conditions
Keywords
rheumatoid arthritis, rheumatism, Acellbia, methotrexate, biologic therapy, monoclonal antibody, rituximab
Brief summary
The mail goal of this study is to establish superiority in efficacy of Acellbia® applied in a dose of 600 mg (Day 1 and Day 15) in combination with methotrexate in patients with active RA seropositive previously untreated with biological therapy, compared to standard therapy with methotrexate.
Interventions
BIOLOGICALAcellbia
Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
DRUGPlacebo
Placebo solution will look identical to the Acellbia solution.
DRUGMethotrexate
Sponsors
Biocad
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Written informed consent. Age from 18 to 80 years. Rheumatoid arthritis diagnosed at least 6 months before informed consent signing Presence of more than 8 swollen and more than 8 painful joints at screening. C-reactive protein 7 mg/l or more AND/OR erythrocyte sedimentation rate 28 mm/hour or more. Antibodies to citrullinated cyclic peptide 20 U/ml or more AND/OR rheumatoid factor-IgM higher than upper normal limit. Documented regular methotrexate intake for 12 weeks, stable dose from 10 to 25 mg/week during last 4 weeks before signing informed consent.
Exclusion criteria
Methotrexate intolerance. Felty's syndrome. Patient functional status - IV class according to ACR. Previous use of biologic drugs to treat rheumatoid arthritis, biologic drugs that deplete CD20-lymphocytes, azathioprine use in the last 28 days prior to informed consent signing, leflunomide use in the last 8 weeks prior to informed consent signing, sulphasalazine/hydroxyquinoline use in the last 28 days prior to informed consent signing, intraarticular use of corticosteroids in the last 4 weeks prior to informed consent signing, patient requires prednisolone (or analogues) in a dose more than 10 mg/day or dose is unstable during 4 weeks prior to informed consent signing, requirement in non-steroid antiinflammatory drugs if their dose was not stable during last 8 weeks prior to informed consent signing. Patient has inflammatory joint disease otherwise than rheumatoid arthritis or systemic autoimmune diseases. Full list of inclusion and
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients who developed ACR20 response on 24 week of therapy | Week 24 | The proportion of patients achieving at least a 20% improvement in ACR criteria at 24 weeks of therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients who developed ACR50 and ACR70 response on 24 week of therapy | Week 24 | The proportion of patients achieving at least 50% and 70% improvement in ACR criteria at 24 weeks of therapy. |
| Percentage of patients who developed ACR20, ACR50 and ACR70 response on 16 week of therapy | Week 16 | The proportion of patients achieving at least 20%, 50% and 70% improvement in ACR criteria after 16 weeks of therapy. |
| Change in average DAS28-4 (ESR) score after 24 weeks of therapy | Week 24 | Change in average DAS28-4 (ESR) score after 24 weeks of therapy |
| Change in average HAQ-DI score after 24 weeks of therapy | Week 24 | — |
| Change in average score according to modified Sharp method of assessment after 24 weeks of therapy | Week 24 | — |
| Change in average score of erosions according to modified Sharp method of assessment after 24 weeks of therapy | Week 24 | — |
| Change in average score of joint spase narrowing according to modified Sharp method of assessment after 24 weeks of therapy | Week 24 | — |
| Percentage of patients with progression of disease according to modified Steinbrocker method of assessment after 24 weeks of treatment | Week 24 | — |
| Percentage of patients who developed ACR20, ACR50 and ACR70 response on 52 week of therapy | Week 52 | The proportion of patients achieving at least 20%, 50% and 70% improvement in ACR criteria after 52 weeks of therapy. |
| Percentage of patients who have developed binding and neutralizing antibodies to rituximab on week 24 and week 52 | Week 24, Week 52 | — |
| Change in average HAQ-DI score after 52 weeks of therapy | Week 52 | — |
| Change in average score according to modified Sharp method of assessment after 52 weeks of therapy | Week 52 | — |
| Change in average score of erosions according to modified Sharp method of assessment after 52 weeks of therapy | Week 52 | — |
| Change in average score of joint space narrowing according to modified Sharp method of assessment after 52 weeks of therapy | Week 52 | — |
| Percentage of patients with progression of disease according to modified Steinbrocker method of assessment after 52 weeks of treatment | Week 52 | — |
| Frequency and severity of AE/SAE | 52 weeks | Frequency and severity of AE/SAE in patients who received at least one injection of study drug/placebo |
| Frequency of AE 3-4 grade CTCAE 4.03 | 52 weeks | Frequency of AE 3-4 grade CTCAE 4.03 in patients who received at least one injection of study drug/placebo |
| Frequency of premature withdrawal due to AE/SAE | 52 weeks | — |
| Change in average DAS28-4 (ESR) score after 52 weeks of therapy | Week 52 | Change in average DAS28-4 (ESR) score after 52 weeks of therapy |
Outcome results
None listed